Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization

Journal of the American College of Cardiology

Volumn 32, Issue 2, 1998, Pages 311-319

  Berkowitz, Scott D ^a   Sane, David C ^b   Sigmon, Kristina N ^a   Shavender, Jane H ^a   Harrington, Robert A ^a   Tcheng, James E ^a   Topol, Eric J ^c   Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB;

ADULT; AGED; ARTICLE; COMORBIDITY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; THROMBOCYTOPENIA; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BODY WEIGHT; FEMALE; FORECASTING; HEMORRHAGE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL ISCHEMIA; PLACEBOS; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; RISK FACTORS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0032145428     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00252-6     Document Type: Article

References (23)

1. Scharf R.E., Tomer A., Marzec U.M., Teirstein P.S., Ruggeri Z.M., Harker L.A. Activation of platelets in blood perfusion angioplasty-damaged coronary arteries flow cytometric detection . Arterioscler Thromb. 12:1992;1475-1487.
2. Tschoepe D., Schultheib H.P., Kolarov P., et al. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCR. Circulation. 88:1993;37-42.
3. Owen J., Hunter-Laszlo M., Williams J.K., Adams M. Thrombin activity induced by balloon angioplasty of the coronary artery in Macaca fascicularis (cynomolgus monkey). Blood Coag Fibrinolysis. 1:1990;505-507.
4. Schwartz L., Bourassa M.G., Lesperance J., et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 381:1988;1714-1719.
5. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
6. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336:1997;1689-1696.
7. Topol E.J., Califf R.M., Weisman H.F., et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis results at six months . Lancet. 343:1994;881-886.
8. Bovill EG, Terrin ML, Stump DC, et al., for the TIMI investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med 1991;115:256-65.
9. Landefeld C.S., Cook E.F., Flatley M., Weisberg M., Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 82:1987;703-713.
10. Aguirre FV, Topol EJ, Ferguson JJ, et al., for the EPIC Investigators. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 1995;91:2882-90.
11. Berkowitz S.D., Harrington R.A., Rund M.M., Tcheng J.E. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy. Circulation. 95:1997;809-813.
12. Kereiakes D.J., Essell J.H., Abbottsmith C.W., Broderick T.M., Runyon J.P. Abciximab-associated profound thrombocytopenia therapy with immunoglobulin and platelet transfusion . Am J Cardiol. 78:1996;1161-1163.
13. Tcheng J.E., Ellis S.G., George B.S., et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
14. Boughton B.J., Cooke R.M., Smith N.A., Simpson A.W. Autoimmune thrombocytopenia anti-glycoprotein IIb/IIIa auto antibodies are reduced after human anti-D immunoglobulin treatment . Autoimmunity. 18:1994;141-144.
15. Curtis B.R., McFarland J.G., Wu G.G., Visentin G.P., Aster R.H. Antibodies in sulfonamide-induced immune thrombocytopenia recognize calcium-dependent epitopes on the glycoprotein IIb/IIIa complex. Blood. 84:1994;176-183.
16. Jordan R.E., Wagner C.L., Mascelli M.A., et al. Preclinical development of c7E3 Fab a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans . Horton M.A. Adhesion Receptors as Therapeutic Targets. 1996;281-302 CRC Press, New York.
17. Frelinger A.L. 3d, Cohen I., Plow E.F., et al. Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J Biol Chem. 265:1990;6346-6352.
18. Bednar B., Bednar R.A., Cook J.J., et al. Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia [abstract]. Circulation. 94:(Suppl I):1996;I-99.
19. Coller B.S., Scudder L.E., Beer J., et al. Monoclonal antibodies to platelet glycoprotein IIb/IIIa as antithrombotic agents. Ann NY Acad Sci. 614:1991;193-213.
20. Simoons M.L., de Boer M.J., van den Brand M.J., et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 89:1994;596-603.
21. Faulds D., Sorkin E.M. Abciximab (c7E3 Fab) a review of its pharmacology and therapeutic potential in ischaemic heart disease . Drugs. 48:1994;583-598.
22. Harrington R.A., Sane D.C., Califf R.M., et al. Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction the Thrombolysis and Angioplasty in Myocardial Infarction study group . J Am Coll Cardiol. 23:1994;891-898.
23. Rao AK, Pratt C, Berke A, et al., for the TIMI Investigators. Thrombolysis in Myocardial Infarction (TIMI) trial phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.